Clinical Trial Update: Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial [Phase 2]

View source ↗

Summary

Phase 2 clinical trial (DOROTHY) evaluating dose-reduced docetaxel with cyclophosphamide for vulnerable older women with Stage I-III HER2-negative breast cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Status: RECRUITING